Esophageal cancer · 7 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
FOLFOX4 and RT Variant #01 | — | R 6 151 | 35d | — | — | ~1 | ~R 6 151 indirect | — |
Cisplatin and Docetaxel (DC) and RT Variant #01 | — | R 4 778 | 35d | — | — | ~1 | ~R 4 778 indirect | — |
Cisplatin and Paclitaxel (TP) and RT Variant #01 | — | R 2 425 | 21d | — | — | ~1 | ~R 2 425 PFS proxy · indirect | 1 |
Cisplatin and Fluorouracil (CF) and RT Variant #01 | — | R 1 774 | 17d | ~16.0 mo | ~44.1 mo | ~1 | ~R 1 774 PFS proxy · indirect | 4 |
Capecitabine and Cisplatin (CX) and RT Variant #01 Partial | — | — | 7d | — | ~34.5 mo | ~1 | — | 1 |
Radiation therapy N/A - radiation | — | — | 49d | — | ~9.2 mo | — | — | 1 |
S-1 and RT Variant #01 Partial | — | — | 42d | — | — | ~1 | — | 1 |
7 of 7 regimens shown